Literature DB >> 18853416

Neuroendocrine tumor epidemiology: contrasting Norway and North America.

Oyvind Hauso1, Bjorn I Gustafsson, Mark Kidd, Helge L Waldum, Ignat Drozdov, Anthony K C Chan, Irvin M Modlin.   

Abstract

BACKGROUND: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program has proven to be a significant resource in US neuroendocrine tumor (NET) epidemiology. Norway also holds a robust and detailed cancer registry: the Norwegian Registry of Cancer (NRC).
METHODS: SEER NET data were compared with corresponding NRC data in the time period 1993 to 2004 to determine whether there are differences in NET epidemiology between Norway and the United States.
RESULTS: The SEER and NRC reported 17,312 and 2030 NETs, respectively. The overall Caucasian SEER NET incidence was 4.44, compared with 3.24 in the NRC. In the SEER white subset, bronchopulmonary NETs were the most common (incidence = 1.42; 32% of all NETs), compared with small intestinal NETs in the NRC (0.81; 26%). A marked increase in SEER NET incidence (37%-40%) was observed in the period 2000 to 2004, compared with 1993 to 1997; an even more pronounced increase (72%) was seen in the NRC. African Americans exhibited a remarkably high overall NET incidence of 6.50; furthermore, among African Americans, rectal NETs were most common (1.65; 27%). Small intestinal NET incidence was approximately 30% higher in men compared with women in all populations. The highest 5-year survival rates were for rectal NETs (74%-88%) in both databases, whereas prostatic NETs had the worst outcome (0%-23%). At diagnosis, NETs were localized in 27% to 46% of patients.
CONCLUSIONS: NET incidence in the US Caucasian population and in Norway is similar, but considerably higher ( approximately 50%) among African Americans. NETs have been regarded as indolent tumors; however, the 5-year survival is only approximately 55%.

Entities:  

Mesh:

Year:  2008        PMID: 18853416     DOI: 10.1002/cncr.23883

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  164 in total

1.  Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.

Authors:  Lingaku Lee; Hisato Igarashi; Nao Fujimori; Masayuki Hijioka; Ken Kawabe; Yoshinao Oda; Robert T Jensen; Tetsuhide Ito
Journal:  Jpn J Clin Oncol       Date:  2015-09-15       Impact factor: 3.019

2.  IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.

Authors:  Sara Massironi; Alessandro Del Gobbo; Federica Cavalcoli; Stefano Fiori; Dario Conte; Alessio Pellegrinelli; Massimo Milione; Stefano Ferrero
Journal:  Endocrine       Date:  2017-02-17       Impact factor: 3.633

3.  Cytological Ki-67 in pancreatic endocrine tumors: a new "must"?

Authors:  Giulia Franchi; Marco F Manzoni
Journal:  Gland Surg       Date:  2014-11

4.  Clinicopathological features and survival analysis of gastroenteropancreatic neuroendocrine neoplasms: a retrospective study in a single center of China.

Authors:  Xuelong Jiao; Yujun Li; Hongyan Wang; Shanglong Liu; Dongfeng Zhang; Yanbing Zhou
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

5.  Long-term outcome of laparoscopic surgery for pancreatic neuroendocrine tumors.

Authors:  Sven-Petter Haugvik; Irina Pavlik Marangos; Bård Ingvald Røsok; Ewa Pomianowska; Ivar Prydz Gladhaug; Oystein Mathisen; Bjørn Edwin
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

6.  Extensive multiarterial resection attending total duodenopancreatectomy and adrenalectomy for MEN-1-associated neuroendocrine carcinomas.

Authors:  Vyacheslav Ivanovich Egorov; Alexander Felixovich Kharazov; Alla Ivanovna Pavlovskaya; Roman Valeryevich Petrov; Natalia Sergeevna Starostina; Eugeny Valerievich Kondratiev; Ekaterina Mikhailovna Filippova
Journal:  World J Gastrointest Surg       Date:  2012-10-27

7.  Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid.

Authors:  Balasubramanian Venkitaraman; Sellam Karunanithi; Arvind Kumar; G C Khilnani; Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

8.  Ki-67 is a reliable pathological grading marker for neuroendocrine tumors.

Authors:  Ashlie Nadler; Moises Cukier; Corwyn Rowsell; Sepideh Kamali; Yael Feinberg; Simron Singh; Calvin H L Law
Journal:  Virchows Arch       Date:  2013-04-16       Impact factor: 4.064

9.  Diagnosis and treatment of a rare sinonasal neuroendocrine tumour: adding to the evidence.

Authors:  Aashrai Gudlavalleti; Ryan Dean; Yuxin Liu; Amit S Dhamoon
Journal:  BMJ Case Rep       Date:  2016-09-13

10.  Multifocality in Small Bowel Neuroendocrine Tumors.

Authors:  Alexandra Gangi; Emily Siegel; Galinos Barmparas; Simon Lo; Laith H Jamil; Andrew Hendifar; Nicholas N Nissen; Edward M Wolin; Farin Amersi
Journal:  J Gastrointest Surg       Date:  2017-11-08       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.